Attorney General John M. Formella is urging Granite Staters to check their eligibility for compensation related to certain generic drug purchases following preliminary approval of a multistate plan to distribute millions of dollars in settlement funds obtained from generic drug manufacturers. This month, the U.S. District Court for the District of Connecticut granted preliminary approval of a plan filed by New Hampshire and a coalition of 47 other states and territories to distribute settlement funds from settlements resolving claims that generic drug manufacturers unlawfully conspired to raise the prices of certain medications.

“New Hampshire is committed to protecting consumers and holding companies accountable when they engage in conduct that harms competition and drives up prices,” said Attorney General Formella. “I encourage Granite Staters who purchased eligible generic medications to visit the settlement website, check their eligibility, and determine whether they qualify for compensation.”

The coalition previously announced settlements with Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure, totaling approximately $96.5 million. The distribution plan aims to return millions of dollars from those settlements to consumers who may have been harmed by elevated prices for the generic drugs covered by the settlements.

How to file a claim

Consumers who purchased a generic drug listed here between May 2009 and December 2019 may be eligible for compensation.
To determine eligibility and learn how to submit a claim, consumers can:

New Hampshire is part of a coalition of nearly all states and territories pursuing antitrust claims against generic drug manufacturers. The litigation began in 2016 and involves allegations that pharmaceutical companies and their executives engaged in unlawful agreements to limit competition and increase the prices of generic medications.

The states’ cases are supported by evidence gathered through extensive investigations, including millions of documents, telephone records, and information from cooperating witnesses. The multistate litigation involves claims against multiple manufacturers and executives concerning various generic drugs. The defendants’ liability remains at issue in the ongoing litigation.

In addition to New Hampshire, the following states and territories joined in the announcement: Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.

The New Hampshire Department of Justice Consumer Protection and Antitrust Bureau investigates unfair, deceptive, or unreasonable practices involving New Hampshire consumers.  To file a complaint with the New Hampshire Department of Justice, visit https://www.doj.nh.gov/consumer/complaints.